Boston Scientific (NYSE: BSX) announced today that the FDA has approved three of its cardiac products. The news is a bit of a bright spot amidst an ongoing restructuring effort expected to cut some 2,300 jobs at the Natick, MA-based firm, and follows on the heels of the news that it had lost a $431 million patent-infringement suit—a decision the company intends to fight.
All three of the newly approved products come out of Boston Scientifics’ cardiac rhythm management business, which was combined with the company’s electrophysiology business as part of the restructuring plan announced in October. Two of the products—the Confient ICD and the Livian CRT-D—are implantable devices for regulating and defibrillating cardiac patients’ hearts. The third product is an upgraded version of the Latitude patient management system, a wireless system that allows doctors to monitor patients with implanted devices such as the Confient and the Livian in their homes. “These technologies are welcome improvements that are designed to provide earlier insight into changing patient conditions and enable me to devote time to patients who need me the most,” said University of Iowa professor of medicine Brian Olshansky in the Boston Scientific statement.